Onkologie. 2023:17(3):205-208 | DOI: 10.36290/xon.2023.041

Patient with upgrading ganglioglioma

Marek Šlachta1, Ondřej Kalita1, Dominik Hraboš2, Lumír Hrabálek1, Martin Doležel3, Jiří Drábek4, Miroslav Vaverka1
1 Neurochirurgická klinika, LF UP a FN Olomouc
2 Ústav molekulární a klinické patologie, LF UP a FN Olomouc
3 Onkologická klinika, LF UP a FN Olomouc
4 Ústav molekulární a translační medicíny, LF UP v Olomouci

Ganglioglioma is a rare primary brain tumor. It is commonly located supratentorialy, in the temporal lobe (>70%). The main clinical manifestation is a drug-resistant epileptic seizures. A rare, anaplastic, form is considered based on histological anaplastic signs of the glial component. Our patient with WHO grade 1 ganglioglioma underwent several surgeries for the gradual neoplasm progression. The histological examination shows the tumor development and its gradual up-grading into an anaplastic form (WHO grade 3), of which biology corresponded with the IDH wild-type glioblastoma. Current molecular-genetic tumor profiling is underpinnings for predilection of the biologic and clinic behavior and also for the assessment of follow-up and treatment strategy.

Keywords: ganglioglioma, anaplastic ganglioglioma, tumor upgrading, glioblastoma, IDH wild-type.

Accepted: June 12, 2023; Published: June 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šlachta M, Kalita O, Hraboš D, Hrabálek L, Doležel M, Drábek J, Vaverka M. Patient with upgrading ganglioglioma. Onkologie. 2023;17(3):205-208. doi: 10.36290/xon.2023.041.
Download citation

References

  1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology [Internet]. 2021;23(8):1231-1251. Available from: doi:10.1093/neuonc/noab106. Go to original source... Go to PubMed...
  2. Greenberg M. Ependymal, Choroid Plexus, & Neuronal Tumors and Other Gliomas In: Greenberg M, Handbook of Neurosurgery ed. New York: Thieme; 2019:662-663.
  3. Rogojan L, Olinici CD. Ganglioglioma with glioblastoma component. Rom J Morphol Embryol. 2008;49(3):403-406. PMID: 18758648.
  4. Pujadas E, Chen L, Rodriguez FJ. Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors. Brain Tumor Pathology [Internet]. 2019;36(2):40-51. Available from: doi:10.1007/s10014-019-00336-z. Go to original source... Go to PubMed...
  5. Luyken C, Blümcke I, Fimmers R, et al. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer. 2004;101(1):146-155. doi: 10.1002/cncr.20332. PMID: 15222000. Go to original source... Go to PubMed...
  6. Lang FF, Epstein FJ, Ransohoff J, et al. Central Nervous System Gangliogliomas. Part 2: Clinical Outcome. J Neurosurg. 1993;79:867-873. Go to original source... Go to PubMed...
  7. Reinhardt A, Pfister K, Schrimpf D, et al. Anaplastic ganglioglioma - A diagnosis comprising several distinct tumour types. Neuropathology and Applied Neurobiology [Internet]. 2022;48(7). Available from: doi:10.1111/nan.12847. Go to original source... Go to PubMed...
  8. Pekmezci M, Javier E, Meyer V, et al. The genetic landscape of ganglioglioma. Acta Neuropathologica Communications [Internet]. 2018;6(1). Available from: doi:10.1186/s40478-018-0551-z. Go to original source... Go to PubMed...
  9. Naydenov E, Tzekov C, Minkin K, et al. Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme-report on two cases and review of the literature. Khirurgiia (Sofiia). 2009;(2-3):69-74. Bulgarian. PMID: 20506796.
  10. Hayashi Y, Iwato M, Hasegawa M, et al. Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Case report. J Neurosurg. 2001;95(1):138-142. doi: 10.3171/jns.2001.95.1.0138. PMID: 11453385. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.